[1]赵津,蔡永红,张莲,等.糖尿病肾脏病发病机制的探讨[J].国际内分泌代谢杂志,2024,44(03):189-193.[doi:10.3760/cma.j.cn121383-20231030-10054]
 Zhao Jin,Cai Yonghong,Zhang Lian,et al.Research progress on pathogenesis of diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2024,44(03):189-193.[doi:10.3760/cma.j.cn121383-20231030-10054]
点击复制

糖尿病肾脏病发病机制的探讨()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
44
期数:
2024年03期
页码:
189-193
栏目:
综述
出版日期:
2024-05-20

文章信息/Info

Title:
Research progress on pathogenesis of diabetic kidney disease
作者:
赵津蔡永红张莲刘建峰赵克中
天津医科大学静海临床学院肾脏内分泌科,天津 301600
Author(s):
Zhao Jin Cai Yonghong Zhang Lian Liu jinfeng Zhao kezhong.
Department of Renal En-docrinology, Jinghai Clinical College, Tianjin Medical University, Tianjin 301600, China
关键词:
生物标志物 糖尿病肾脏病 发病机制
Keywords:
Biomarkers Diabetic kidney disease Pathogenesis
DOI:
10.3760/cma.j.cn121383-20231030-10054
摘要:
糖尿病肾脏病(DKD)是糖尿病最常见的并发症之一,也是终末期肾脏病(ESKD)的主要原因。它的发生和发展涉及3个基本组成部分:血流动力学异常、代谢紊乱和炎症反应。临床上定义该病为伴有肾小球滤过率(eGFR)进行性下降的持续性蛋白尿。然而,由于这些改变不是DKD所特有的,因此有必要从发病机制中探讨新的生物标志物,有助于DKD患者的早期诊断、随访、治疗反应和预后评估。
Abstract:
Diabetic kidney disease(DKD)is one of the most common complications of diabetes mellitus and the main cause of end-stage renal disease(ESKD). Its development involves three fundamental components: the hemodynamic abnormality, metabolic disorder, and inflammatory response. Clinically, persistent albuminuria in association with a progressive decline in glomerular filtration rate(GFR)defines this disease. However, as these alterations are not specific to DKD, there is a need to discuss novel biomarkers arising from its pathogenesis which may aid in the diagnosis, follow-up, therapeutic response, and prognosis of the disease.

参考文献/References:

[1] Pérez-Morales RE,Del Pino MD,Valdivielso JM,et al.Inflammation in diabetic kidney Disease[J].Nephron,2019,143(1):12-16.DOI:10.1159/000493278.
[2] Gupta S,Dominguez M,Golestaneh L.Diabetic kidney disease:an update[J].Med Clin North Am,2023,107(4):689-705.DOI:10.1016/j.mcna.2023.03.004.
[3] Daza-Arnedo R,Rico-Fontalvo JE,Pájaro-Galvis N,et al.Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease:a narrative review[J].Kidney Med,2021,3(6):1065-1073.DOI:10.1016/j.xkme.2021.07.007.
[4] Rico-Fontalvo J,Aroca G,Cabrales J,et al.Molecular mechanisms of diabetic kidney disease[J].Int J Mol Sci,2022,23(15):8668.DOI:10.3390/ijms23158668.
[5] Kidney Disease:Improving Global Outcomes(KDIGO)Diabetes Work Gr-oup.KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J].Kidney Int,2022,102(5S):S1-S127.DOI:10.1016/j.kint.2022.06.008.
[6] Rico-Fontalvo J,Aroca-Martínez G,Daza-Arnedo R,et al.Novel Biomarkers of Diabetic Kidney Disease[J].Biomolecules,2023,13(4):633.DOI:10.3390/biom13040633.
[7] Samsu N.Diabetic nephropathy:challenges in pathogenesis,diagnosis,and treatment[J].BioMed Res Int,2021,2021:1497449.DOI:10.1155/2021/1497449.
[8] Ostermann M,Zarbock A,Goldstein S,et al.Recommendations on acute kidney injury biomarkers from the acute disease quality initiative cons-ensus conference:a consensus statement[J].JAMA Netw Open,2020,3(10):e2019209.DOI:10.1001/jamanetworkopen.2020.19209.
[9] Ren X,Wang W,Cao H,et al.Diagnostic value of serum cathepsin S in type 2 diabetic kidney disease[J].Front Endocrinol(Lausanne),2023,14:1180338.DOI:10.3389/fendo.2023.1180338.
[10] Wei J,Wang B,Shen FJ,et al.Diagnostic value of triglyceride and cystatin C ratio in diabetic kidney disease:a retrospective and prospective cohort study based on renal biopsy[J].BMC Nephrol,2022,23(1):270.DOI:10.1186/s12882-022-02888-3.
[11] He P,Bai M,Hu JP,et al.Significance of neutrophil gelatinase-associated lipocalin as a biomarker for the diagnosis of diabetic kidney disea-se:a systematic review and meta-analysis[J].Kidney Blood Press Res,2020,45(4):497-509.DOI:10.1159/000507858.
[12] Duan S,Chen J,Wu L,et al.Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease[J].J Diabetes Complicat,2020,34(10):107665.DOI:10.1016/j.jdiacomp.2020.107665.
[13] Abbasi F,Moosaie F,Khaloo P,et al.Neutrophil gelatinase-associated lipocalin and retinol-binding protein-4 as biomarkers for diabetic kidney disease[J].Kidney Blood Press Res,2020,45(2):222-232.DOI:10.1159/000505155.
[14] Swaminathan SM,Rao IR,Shenoy SV,et al.Novel biomarkers for prognosticating diabetic kidney disease progression[J].Int Urol Nephrol,2023,55(4):913-928.DOI:10.1007/s11255-022-03354-7.
[15] Takao T,Yanagisawa H,Suka M,et al.Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes:the Asahi diabetes complications study[J].J Diabetes Investig,2022,13(2):299-307.DOI:10.1111/jdi.13659.
[16] Tye SC,Denig P,Heerspink HJL.Precision medicine approaches for diabetic kidney disease:opportunities and challenges[J].Nephrol Dial Transplant,2021,36(Suppl 2):3-9.DOI:10.1093/ndt/gfab045.
[17] DeFronzo RA,Reeves WB,Awad AS.Pathophysiology of diabetic kidney disease:impact of SGLT2 inhibitors[J].Nat Rev Nephrol,2021,17(5):319-334.DOI:10.1038/s41581-021-00393-8
[18] Sen T,Li J,Neuen BL,et al.Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1,TNFR-2 and KIM-1 in the CANVAS trial[J].Diabetologia,2021,64:2147-2158.DOI:10.1007/s00125-021-05512-5.
[19] Bletsa E,Filippas-Dekouan S,Kostara C,et al.Effect of dapagliflozin on urine metabolome in patients with type 2 diabetes[J].Clin Endocrino-l Metab,2021,106(5):1269-1283.DOI:10.1210/clinem/dgab086.
[20] Gutiérrez OM,Shlipak MG,Katz R,et al.Associations of plasma biomarkers of inflammation,fibrosis,and kidney tubular injury with progression of diabetic kidney disease:a cohort study[J].Am J Kidney Dis,2022,79(6):849-857.e1.DOI:10.1053/j.ajkd.2021.09.018.
[21] Goriuc A,Cojocaru KA,Luchian I,et al.Using 8-Hydroxy-2'-Deoxiguanosine(8-OHdG)as a reliable biomarker for assessing periodontal disease associated with diabetes[J].Int J Mol Sci,2024,25(3):1425.DOI:10.3390/ijms25031425.
[22] Yoon SY,Kim JS,Jeong KH,et al.Acute kidney injury:biomarker-guided diagnosis and management[J].Medicina(Kaunas),2022(Kaunas)58(3):340.DOI:10.3390/medicina58030340.
[23] Hasson D,Menon S,Gist KM.Improving acute kidney injury diagnostic precision using biomarkers[J].Pract Lab Med,2022,30:e00272.DOI:10.1016/j.plabm.2022.e00272.

相似文献/References:

[1]张盈莹,卓永,欧佩,等.尿NGAL及KIM-1水平对藏区糖尿病 肾脏病的临床诊断价值研究[J].国际内分泌代谢杂志,2020,40(05):294.[doi:10.3760/cma.j.cn121383-20200502-05027]
 Zhang Yingying,Zhuo Yong,Ou Pei,et al.The clinical diagnostic value of urine NGAL and KIM-1 in diabetic kidney disease in Tibet area of China[J].International Journal of Endocrinology and Metabolism,2020,40(03):294.[doi:10.3760/cma.j.cn121383-20200502-05027]
[2]蒋艺婕,张红,华飞.铁代谢与糖尿病肾脏病的关系研究[J].国际内分泌代谢杂志,2021,41(05):468.[doi:10.3760/cma.j.cn121383-20210218-02037]
 Jiang Yijie,Zhang Hong,Hua Fei..Research on the relationship between iron metabolism and diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2021,41(03):468.[doi:10.3760/cma.j.cn121383-20210218-02037]
[3]蒋俊兰 刘尚全.血尿酸/肌酐比值与早期糖尿病肾脏病进展的关系[J].国际内分泌代谢杂志,2022,42(01):17.[doi:10.3760/cma.j.cn121383-20201024-10029]
 Jiang Junlan,Liu Shangquan..Relationship between serum uric acid to creatinine ratio and progression of early diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2022,42(03):17.[doi:10.3760/cma.j.cn121383-20201024-10029]
[4]文婧怡,郭立新.急性高糖诱发肾小管相关白蛋白尿的发病机制[J].国际内分泌代谢杂志,2022,42(03):195.[doi:10.3760/cma.j.cn121383-20210302-03003]
 Wen Jingyi,Guo Lixin..Pathogenesis of acute hyperglycemia-induced renal tubular-associated albuminuria[J].International Journal of Endocrinology and Metabolism,2022,42(03):195.[doi:10.3760/cma.j.cn121383-20210302-03003]
[5]赵耕 牛文彦.中性粒细胞明胶酶相关脂质运载蛋白在代谢相关肾损伤中的应用价值分析[J].国际内分泌代谢杂志,2022,42(04):272.[doi:10.3760/cma.j.cn121383-20210928-09084]
 Zhao Geng,Niu Wenyan..Application value of neutrophil gelatinase related lipid carrier protein in metabolism related renal injury[J].International Journal of Endocrinology and Metabolism,2022,42(03):272.[doi:10.3760/cma.j.cn121383-20210928-09084]
[6]乐颖,蒋科威,薛萌,等.microRNA-31对高糖条件下人足细胞上皮-间充质转分化的影响[J].国际内分泌代谢杂志,2022,42(05):354.[doi:10.3760/cma.j.cn121383-20210426-04077]
 Le Ying,Jiang Kewei,Xue Meng,et al.Effects of microRNA-31 on high-glucose induced epithelial-mesenchymal transition of podocytes[J].International Journal of Endocrinology and Metabolism,2022,42(03):354.[doi:10.3760/cma.j.cn121383-20210426-04077]
[7]张清,叶晓萍,胥勋梅,等.紫苏叶提取物对糖尿病肾脏病大鼠肾纤维化及Notch/Snail1信号通路的影响[J].国际内分泌代谢杂志,2024,44(03):150.[doi:10.3760/cma.j.cn121383-20231128-11064]
 Zhang Qing,Ye Xiaoping,Xu Xunmei,et al.Effects of Perilla leaf extract on renal fibrosis and Notch/Snail1 signaling pathway in diabetic kidney disease rats[J].International Journal of Endocrinology and Metabolism,2024,44(03):150.[doi:10.3760/cma.j.cn121383-20231128-11064]

备注/Memo

备注/Memo:
通信作者:赵克中,Email:kzz2568@163.com
更新日期/Last Update: 2024-05-30